Gonzales et al. conducted an open-label phase 1 clinical trial of rapamycin for mild cognitive impairment and dementia due to Alzheimer’s disease. Rapamycin is not detected in cerebrospinal fluid before or after treatment, but there are changes in multiple neurodegenerative diseases and inflammatory biomarkers from baseline to post-treatment.
- Mitzi M. Gonzales
- Valentina R. Garbarino
- Dean Kellogg Jr
